Adaptimmune Data to be Presented at American Society of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
143
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study

PHILADELPHIA, Pa. and OXFORD, UK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, will have updated data from its completed pilot study 1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented at the annual ASH meeting at the Georgia World Congress Center in Atlanta, Ga.

During an oral presentation, Dr. Edward Stadtmauer, University of Pennsylvania Abramson Cancer Center, will present an update on all twenty-five multiple myeloma patients treated in Adaptimmune’s pilot study in the setting of ASCT. The data cut-off for the abstract was through July 2017, the data cut-off for the oral presentation was August 16, 2017.

Oral Presentation 845:  Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow‑up (NCT01352286)

Session: 703. Adoptive Immunotherapy: Gene Engineered T cells for Hematologic Malignancies

Time: Monday, December 11, 2017: 5:30 PM (EST)

Location: Bldg. B, Level 2, B206 (Georgia World Congress Center)

Result highlights from the abstract include:

  • Overall response rate (ORR) at day 100 was 76% (1 stringent complete response [sCR]; 12 very good partial response [VGPR]; 6 partial response [PR])
  • At year 1, 13 patients were progression free (52%) of which 11 were responders (1 sCR; 1 CR; 8 VGPR; 1 PR)
  • Three patients remain disease progression-free at 39, 56, and 61 months post T-cell infusion
  • Median progression free survival (PFS) was ~13 months (range 3-61 months)
  • Eleven of 25 patients (44%) are alive, and median survival was ~35 months (range 6-68 months)
  • Autologous GvHD (24%) was reported in 6 patients (3 G3, 3 ≤G2); all resolved with corticosteroids and supportive therapy
  • No fatal adverse events have been reported

About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE: GSK ) (NYSE: GSK ) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations: Sébastien Desprez – VP, Communications and Investor Relations T: +44 1235 430 583 M: +44 7718 453 176 Sebastien.Desprez@adaptimmune.com

Investor Relations: Juli P. Miller, Ph.D. – Director, Investor Relations T: +1 215 825 9310 M: +1 215 460 8920 Juli.Miller@adaptimmune.com

________________________

1 This study closed for enrollment in 2015. All NY-ESO studies will ultimately transition to GSK as part of its option exercise over Adaptimmune’s NY‑ESO SPEAR T-cell therapy program that was announced in September 2017.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 9

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 34

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 23

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Everyday Dose Tests Coffee in a New Pocket Format Today

Updated Category News Views 22

Coffee has finally wandered into the candy aisle, and I cannot decide whether that is clever or mildly exhausting. Everyday Dose and Austin-based Le Lick have launched Le Latte, a limited-batch coffee-flavored electrolyte lollipop aimed at adults who want caffeine without hauling around a cup. It is an odd little product, sure, but odd is often where consumer brands find...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 89

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 76

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 155

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 40

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
DoorDash Grocery Tools Need a Hard Look Before Checkout

Updated Category News Views 95

A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...

Continue Reading

Top 5 Most Recently Viewed Articles

Jyske Realkredit A/S Announces New Bond Listing Details

Updated Category News Views 192

Key Announcement about New Bond Listings On August 20, Jyske Realkredit A/S is set to introduce new bonds to the market. This announcement signals a pivotal moment for investors and the financial community alike. The company is preparing to list a novel type of Covered Bond (SDO) and a Mortgage Bond (RO), which could have significant implications for the current market...

Continue Reading
Maze Therapeutics Engages Investors at Major BioConnect Event

Updated Category News Views 168

Maze Therapeutics Engages Investors at a Major Event Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, is making waves in the healthcare industry with its innovative approach to developing small molecule precision medicines. Their focus on addressing renal, metabolic, and cardiovascular diseases underscores the company's commitment to...

Continue Reading
Iterum Therapeutics Successfully Completes $5 Million Offering

Updated Category News Views 161

Iterum Therapeutics Completes Significant Offering Iterum Therapeutics plc (NASDAQ: ITRM), a biopharmaceutical company dedicated to creating innovative solutions against multi-drug resistant pathogens, has officially announced the successful closure of its recent direct offering. This strategic fundraising effort resulted in the sale of 5,555,556 ordinary shares, or the...

Continue Reading
Shopify Achieves Unprecedented Milestone with $14.6 Billion Sales

Updated Category News Views 210

Shopify's Impressive Holiday Sales Growth Shopify Inc. (NASDAQ: SHOP) has recently announced a phenomenal achievement, showcasing that merchants on its platform generated a staggering $14.6 billion in sales during the holiday shopping weekend. This impressive figure marks a magnificent 27% increase compared to the previous year, with approximately 81 million customers...

Continue Reading
Hotel Okura and AWC Set to Launch Unique Ryokan Hotels

Updated Category News Views 305

Hotel Okura and AWC Announce New Ryokan-Style Hotels In an exciting development for Thailand's hospitality sector, Hotel Okura Co., Ltd., a leading global player in the Japanese hotel industry, has partnered with Asset World Corporation (AWC). This collaboration will bring two new ryokan-style hotels to Chiang Mai and Bangkok, both slated to open by the year 2028. This...

Continue Reading